



## NKS L Symposium 2019

# EU-Projekte mit Impact: Erwartungen, Umsetzung, Erfolge



SCANDIC Frankfurt  
1. Oktober 2019

**Dirk Hadrich**  
**Healthy Lives, Microbiome**  
**Research & Innovation**  
**European Commission**

## Directorate E - People

Director - I. NORSTEDT (acting)

**E1 - Healthy Lives - A. LONNROTH**

E2 - Combatting Diseases - B. KERSTIENS

E3 - Health Innovations - M. AGUAR  
FERNANDEZ

E4 - Fair Societies & Cultural Heritage - H.  
HARTUNG

E5 - Democracy & European Values - H.  
HARTUNG (acting)

E6 - Economic & Social Transitions - I.  
NORSTEDT

1. Topics
2. Evaluierung
3. Umsetzung
4. Zukunft

# Topics

## 1. Portfolio Analyse

- Trends
- Herausforderungen

## 2. Drafting

**SC1-BHC-03-2018: Exploiting research outcomes human microbiome for personalised prediction, pre**

**Specific Challenge:** The human microbiome plays different projects in 'metagenomics' and epidemiolo

**Scope:**

Proposals should build on data from  
They should combine and expand these

**Expected Impact:**

- More valuable clinical tools built on relevant repositories.
- Identification and validation of m determinants of resilience for defu



# Politische Diskussionen & Strategien

- F&I treibt Wachstum & Beschäftigung
- Bildung von neuen Märkten durch KMU
- Co-creation, Einbindung der Bürger/Patienten
- Oversubscription
- Real-life Implementation
- Digitale Tools für schnelle Entscheidungen
- Personalisiert & patienten-orientiert
- Internat. Zusammenarbeit (Mehrfach-Funding)
- Proaktiv statt reaktiv
- Ergebnisse, Auswirkungen & Durchbruch **2X**



# HEALTH.2012.1.2-1: Development of technologies with a view to patient group stratification for personalised medicine applications

**Expected impact:** The development of new and improved tools and technologies should contribute to enabling the uptake of personalised medicine into clinical practice and support the competitiveness of Europe in this area. The projects are expected to advance research in personalised medicine and have an impact in the relevant industry (in particular for SMEs).



# SC1-BHC-03-2018: Exploiting research outcomes and application potential of the human microbiome for personalised prediction, prevention and treatment of disease

- Identification and **validation** of microbial functionalities; robust healthy conditions and determinants of resilience for defined populations at specific body sites.
- Better prediction and prevention of diseases through **validated** novel clinical tools that are helpful for end-users.



# Evaluierung der Vorschläge

- Auswahl von unabhängigen Experten
- Individuelle- & Team-Evaluierung
- 3 Kriterien:
  - Exzellenz, Impact, Umsetzung
- Stärken & Schwächen
- Ranking



# GAP & Projekt-Umsetzung

- Operationelle Kapazität
- Klar, konkret, eindeutig (Arbeitsplan, Deliverables, Impact, Deadlines, Ethische Aspekte)
- Kommunikation, Dissemination, Management, ext.SAB, ext.Eth.Advisor
- Periodische Berichte (18M)
- Review, Korrekturen, Delays, Verlängerung
- Indikatoren für & Messung von Impact





## Health topic 'SC1-BHC-03-2018':

**"Exploiting research outcomes and application potential of the human microbiome for personalised prediction and prevention of disease"**


- Existing data and new complementary data
- Functionalities, healthy conditions, resilience
- -omics, dietary data, lifestyle, ...
- Clinical tools for predicting and preventing
- € 10-15 M (total budget € 50 M)

→ Deadline 18 April 2018: 27 applications

# ONCOBIOME

2019-2023  
€15M

- Gut Microbiome Signatures for 4 types of cancer (“Cancer Microbiota Atlas”)
- large cohorts enrolling



>9,000 cancer patients across 10 countries

Laurence ZITVOGEL


- Prediction of responses (chemo- / immuno-therapies)
- Influence cancer progression (companion diagnostic tests)

[http://cordis.europa.eu/home\\_en.html](http://cordis.europa.eu/home_en.html)

# MICROB-PREDICT

2019-2024 €15M

- Acute-on-chronic liver failure
- Microbiome data of >10.000 patients
- Find functional microbial traits and interactions
- Validated tools for clinical and therapeutic decisions
- Easy-to-use nanobiosensors (PoC)
- Patient Organisation involved




Jonel TREBICKA

# GEMMA

## 2019-2023

### €14,2M

- Autism
- Involves 600 at-risk infants
- Understand multifactorial risks
- Interactions between gut microbiome, intestinal barrier and immune response
- Integrative analytical platform using Artificial Intelligence and multi-omics
- Preventive nutritional formulation



autismspeaks.org  
CDC estimate 2018  
Alessio FASANO

# Zukunft

- Linking, Co-creation & Multi-Disziplinär
- Internationale Zusammenarbeit
- Standardisierung
- Fokus auf Impact:
  - Tools, Produkte, Anwendungen
- Horizon Europe 2021-2027
  - Lab-Fab-App report (Lamy)
  - Mehr Impact & Relevanz & Durchbruch
  - Missions & Zusammenarbeit